Real-world Glycemic Outcomes of a Tubeless Automated Insulin Delivery System (Medtrum A8 TouchCare) in Adults With Type 1 Diabetes

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Canadian Journal of Diabetes Pub Date : 2026-08-01 Epub Date: 2026-05-22 DOI:10.1016/j.jcjd.2026.05.004

Michele Roberto Modestino MD, Mariarosaria De Luca MD, Umberto De Fortuna MD, Laura Ferrentino MD, Olimpia Iacono MD, Rita Verdoliva MD, Angelo Foglia MD, Vincenzo Guardasole MD

{"title":"Real-world Glycemic Outcomes of a Tubeless Automated Insulin Delivery System (Medtrum A8 TouchCare) in Adults With Type 1 Diabetes","authors":"Michele Roberto Modestino MD, Mariarosaria De Luca MD, Umberto De Fortuna MD, Laura Ferrentino MD, Olimpia Iacono MD, Rita Verdoliva MD, Angelo Foglia MD, Vincenzo Guardasole MD","doi":"10.1016/j.jcjd.2026.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Automated insulin delivery (AID) systems are recommended as a first-line therapy for type 1 diabetes. The Medtrum A8 TouchCare is a tubeless AID system powered by the APGO algorithm, which modulates basal insulin and delivers automatic correction microboluses. Real-world evidence on this system remains extremely limited. In this study, we aimed to evaluate the efficacy of the Medtrum A8 TouchCare in AID mode in a real-world cohort of adults with type 1 diabetes.</div></div><div><h3>Methods</h3><div>We conducted a single-centre, observational retrospective study at Federico II University Hospital, Naples, Italy (January to October 2025). Adults with type 1 diabetes of ≥6 months’ duration who were using the Medtrum A8 TouchCare in AID mode were included. Continuous glucose monitoring metrics and clinical parameters were compared at baseline and after 3 months. The primary endpoint was the change in time in range.</div></div><div><h3>Results</h3><div>A total of 20 patients were included (mean age: 39±6 years; diabetes duration: 18±6 years). After 3 months, time in range increased by 12.51% (p<0.05); time above range 1 and time above range 2 decreased by 7.2% (p<0.05) and 5.97% (p<0.05), respectively. Glucose monitoring index improved by 0.46% (p<0.05) and glycemia risk index by 13.75 points (p<0.05), and glycated hemoglobin decreased by 0.52% (p<0.05). No significant changes were observed in time below range 1, time below range 2, or coefficient variability, and no severe hypoglycemia episodes occurred.</div></div><div><h3>Conclusions</h3><div>The Medtrum A8 TouchCare in AID mode significantly improved glycemic management without increasing hypoglycemia. These findings support the efficacy of this tubeless AID system and warrant confirmation in larger prospective studies.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"50 6","pages":"Pages 423-428"},"PeriodicalIF":2.7000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S149926712600095X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Automated insulin delivery (AID) systems are recommended as a first-line therapy for type 1 diabetes. The Medtrum A8 TouchCare is a tubeless AID system powered by the APGO algorithm, which modulates basal insulin and delivers automatic correction microboluses. Real-world evidence on this system remains extremely limited. In this study, we aimed to evaluate the efficacy of the Medtrum A8 TouchCare in AID mode in a real-world cohort of adults with type 1 diabetes.

Methods

We conducted a single-centre, observational retrospective study at Federico II University Hospital, Naples, Italy (January to October 2025). Adults with type 1 diabetes of ≥6 months’ duration who were using the Medtrum A8 TouchCare in AID mode were included. Continuous glucose monitoring metrics and clinical parameters were compared at baseline and after 3 months. The primary endpoint was the change in time in range.

Results

A total of 20 patients were included (mean age: 39±6 years; diabetes duration: 18±6 years). After 3 months, time in range increased by 12.51% (p<0.05); time above range 1 and time above range 2 decreased by 7.2% (p<0.05) and 5.97% (p<0.05), respectively. Glucose monitoring index improved by 0.46% (p<0.05) and glycemia risk index by 13.75 points (p<0.05), and glycated hemoglobin decreased by 0.52% (p<0.05). No significant changes were observed in time below range 1, time below range 2, or coefficient variability, and no severe hypoglycemia episodes occurred.

Conclusions

The Medtrum A8 TouchCare in AID mode significantly improved glycemic management without increasing hypoglycemia. These findings support the efficacy of this tubeless AID system and warrant confirmation in larger prospective studies.

查看原文本刊更多论文

无管自动胰岛素输送系统（Medtrum A8 TouchCare）治疗成人1型糖尿病患者的实际血糖结局

背景：自动胰岛素输送（AID）系统被推荐作为1型糖尿病的一线治疗方法。Medtrum A8 TouchCare是一款由APGO算法驱动的无管AID系统，可调节基础胰岛素并提供自动校正微丸。关于这个系统的真实证据仍然非常有限。目的：评价Medtrum A8 TouchCare在AID模式下对成人1型糖尿病患者的疗效。方法：我们于2025年1月至10月在意大利那不勒斯Federico II大学医院进行了一项单中心、观察性、回顾性研究。在AID模式下使用Medtrum A8 TouchCare的持续时间至少6个月的成人1型糖尿病患者被纳入研究。在基线和三个月后比较连续血糖监测指标和临床参数。主要终点是时间范围变化（TIR）。结果：纳入20例患者（平均年龄39±6岁，糖尿病病程18±6年）。3个月后，TIR升高12.51% (p < 0.05)， TAR1和TAR2分别下降7.2% （p < 0.05）和5.97% （p < 0.05）。GMI提高0.46% (p < 0.05)， GRI提高13.75点（p < 0.05）， HbA1c降低0.52% （p < 0.05）。未观察到TBR1、TBR2或CV的显著变化，也未发生严重低血糖发作。结论：Medtrum A8 TouchCare在AID模式下可显著改善血糖控制，但不增加低血糖。这些发现支持了这种无管AID系统的有效性，并需要在更大的前瞻性研究中得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Canadian Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

CiteScore

4.80

自引率

4.00%

发文量

130

审稿时长

54 days

期刊介绍： The Canadian Journal of Diabetes is Canada''s only diabetes-oriented, peer-reviewed, interdisciplinary journal for diabetes health-care professionals. Published bimonthly, the Canadian Journal of Diabetes contains original articles; reviews; case reports; shorter articles such as Perspectives in Practice, Practical Diabetes and Innovations in Diabetes Care; Diabetes Dilemmas and Letters to the Editor.